Dr. med. Sommer II

Implantica announces that RefluxStop™ results were presented at the DDW Conference in Chicago

Retrieved on: 
Tuesday, May 16, 2023

VADUZ, Liechtenstein, May 16, 2023 /PRNewswire/ -- Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dr. med.

Key Points: 
  • VADUZ, Liechtenstein, May 16, 2023 /PRNewswire/ -- Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dr. med.
  • Zehetner, Prof. (USC) from Switzerland, presented Klinik Beau-Site's RefluxStop™ results at Digestive Disease Week (DDW) 6-9 May, in Chicago, U.S., the world's premier meeting for gastrointestinal professionals
    Dr. med.
  • Support from key opinion leaders and clinical data are crucial for Implantica as we work to obtain reimbursement across Europe.
  • "Implantica is also proud to announce that we have started our marketing process in the U.S. preparing the ground for the future U.S. approval.

LR Health & Beauty Enters a New Beauty Era

Retrieved on: 
Tuesday, October 4, 2022

With the launch of its new product, LR Health & Beauty once again proves its innovative strength.

Key Points: 
  • With the launch of its new product, LR Health & Beauty once again proves its innovative strength.
  • View the full release here: https://www.businesswire.com/news/home/20221004005596/en/
    With the launch of the new ZEITGARD PRO COSMETIC DEVICE, LR Health & Beauty once again proves its innovative strength.
  • We are proud to introduce the new ZEITGARD PRO, a real high-tech product that significantly improves the daily beauty routines of our customers.
  • Following the motto More quality for your life, the LR Group with headquarters in Ahlen/Westphalia produces and markets various health and beauty products in 28 countries.

Cambrian BioPharma Appoints Ruth Thieroff-Ekerdt as Executive Vice President of Clinical Development

Retrieved on: 
Wednesday, September 21, 2022

NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice President of Clinical Development.

Key Points: 
  • NEW YORK, Sept. 21, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces the appointment of Ruth Thieroff-Ekerdt, M.D., as Executive Vice President of Clinical Development.
  • "Adding Ruth to the Cambrian team is an important step towards ensuring our work to increase healthspan while creating life-changing medicines for patients suffering from diseases today," said James Peyer, CEO, Cambrian BioPharma.
  • "Her background and vast knowledge of clinical development will allow Cambrian to thoughtfully advance our wide array of programs into human trials."
  • In her role, Dr. Thieroff-Ekerdt will be responsible for a broad range of development activities including the continuation and creation of clinical development and strategy.

DGAP-News: Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer

Retrieved on: 
Thursday, June 23, 2022

Steffen Strzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022.

Key Points: 
  • Steffen Strzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022.
  • Dr. Richard Jones, CEO of Adrenomed, said: We are excited to have Steffen Strzebecher on board to lead Adrenomeds clinical development activities.
  • Dr. Jens Zimmermann, CMO emeritus of Adrenomed, commented: After more than four years at Adrenomed I will be stepping down as Chief Medical Officer due to health reasons.
  • Dr. Strzebecher previously held several executive positions at Grnenthal, including Chief Medical Officer, Head R&D Portfolio Management, Head of Global Development, and Head of Global Medical Sciences.

DGAP-News: Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care

Retrieved on: 
Monday, June 13, 2022

Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care

Key Points: 
  • Debrichem / NHS: Significant cost-effectiveness and better outcomes in VLUs, as published in Journal of Wound Care
    The issuer is solely responsible for the content of this announcement.
  • In total, the NHS could save up to 57% on wound care management costs in treating hard-to-heal VLUs.
  • DEBx Medical aims to support doctors and their patients from diagnosis through treatment, follow-up care and maintenance of a healthy wound bed.
  • DEBx Medical is commercializing Debrichem through a worldwide network covering more than 50 countries, with the first market launches e.g.